{
    "organizations": [],
    "uuid": "0b5ce1c852200abe72aa7ead7cb59c34cb14c687",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-celgene-corp-announces-positive-re/brief-celgene-corp-announces-positive-results-from-the-pivotal-phase-iii-optimismm-study-of-pomalyst-imnovid-idUSFWN1PW0NC",
    "ord_in_thread": 0,
    "title": "BRIEF-Celgene Corp Announces Positive Results From The Pivotal Phase III ‘Optimismm’ Study Of Pomalyst/Imnovid",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 6 (Reuters) - Celgene Corp:\n* CELGENE CORPORATION ANNOUNCES POSITIVE RESULTS FROM THE PIVOTAL PHASE III ‘OPTIMISMM’ STUDY OF POMALYST/IMNOVID® FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA\n* CELGENE CORP - STUDY MET ITS PRIMARY ENDPOINT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-06T20:33:00.000+02:00",
    "crawled": "2018-02-07T22:09:01.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "celgene",
        "corp",
        "celgene",
        "corporation",
        "announces",
        "positive",
        "result",
        "pivotal",
        "phase",
        "iii",
        "optimismm",
        "study",
        "treatment",
        "relapsed",
        "refractory",
        "multiple",
        "myeloma",
        "celgene",
        "corp",
        "study",
        "met",
        "primary",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}